InvoCare Limited shares rise on full year results: Should you buy?

Will InvoCare Limited (ASX:IVC) shares turn it around after the release of its full year results?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in funeral operator InvoCare Limited (ASX: IVC) opened strongly higher today following the release of its full year 2015 results.

At one point, shares gained more than 4.2% and hit a high of $11.35, before giving up some of those gains as the broader market turned into negative territory. At the time of writing, however, InvoCare shares were still holding on to a 2% gain and trading at $11.15.

The shares have been struggling to gain any momentum over the past 12 months, but the market's initial reaction suggests the results were better than expected. Some of the key financial highlights from the results included:

  • Total group sales increased by 5.7% to $436.4 million
  • Funeral case volumes increased by 2.7% over the prior corresponding period (pcp)
  • Operating expenses increased by 6.7% over the pcp
  • EBITDA increased by 4.3% to $105.4 million
  • Net profit after tax (NPAT) increased by 0.6% to $54.8 million
  • Basic earnings per share (EPS) increased by 0.6% to 50.1 cents
  • Final fully franked dividend declared of 22.25 cents per share, bringing the total full year dividend to 38 cents per share, an increase of 4.1% over the pcp
  • Net debt to equity of 109%, down from 117% in the pcp

The company generated reasonable growth in sales, but overall group profitability was impacted by investment costs associated with InvoCare's expansion into the US market. Costs have been higher than first expected and this has been one of the overhanging factors behind InvoCare's lagging share price over the past 12 months. Despite spending $5.7 million on acquisitions and start up costs in FY15, the US operations are yet to turn a profit, and in fact, generated an EBITDA loss of $3.8 million.

Although this will be concerning for some investors, management has stated it is committed to the current strategy and believe no fundamental change is required following a review of the current operations.

Looking past the US operations, InvoCare enjoyed solid trading conditions in Australia, New Zealand and Singapore. The company maintained its market share in all three countries with sizeable market shares of 34% in Australia and New Zealand.

Despite higher operating expenses, margins were maintained throughout the year through the implementation of modest price increases.

InvoCare's prepaid funerals service also continues to perform strongly with a 4.7% increase in the number of contracts sold over the period. The company now holds more than $422 million in funds under management that it is able to earn a return on. Investment returns from these funds decreased in FY15, with net gains on these funds of $7.5 million, down from $10.9 million in FY14.

Outlook

The nature of InvoCare's business means growth in revenues is driven primarily through the increase in the death rate and/or increases in market share. The death rate is expected to grow by around 1% in the short term, with a higher rate expected in the medium to long term as time finally catches up with our ever-increasing ageing population.

Conditions are expected to remain stable in Australia, New Zealand and Singapore, but remain challenging in the newly established US market. As a result, total group sales and earnings growth is expected to remain fairly flat over the next 12 months with stronger growth predicted over the medium term.

Foolish takeaway

Although InvoCare operates in a defensive and predictable sector, I believe it lacks the earnings growth and balance sheet strength to justify its current valuation. The shares are trading at nearly 22x earnings and considering earnings are likely to remain flat over the next 12-24 months, there are far more attractive investment opportunities elsewhere in my opinion.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »